Clay Siegall is the co-founder, President, Chief Executive Officerjv and Chairman of the Board at Seattle Genetics. He is a scientist by training, having received a B.S. in Zoology from the University of Maryland. From George Washington University, he earned a Ph.D. in Genetics. Other than heading Seattle Genetics, Clay Siegall serves on the Boards of Directors of Ultragenyx Pharmaceutical, Mirna Therapeutics, Alder Biopharmaceuticals and Washington Roundtable.

Clay Siegall has a rich history of work experience in the medical field having worked at the National Cancer Institute, National institutes of Health from 1988 to 1991 then as a Senior Research Investigator at Bristol-Myers Squibb Pharmaceutical Research Institute from 1991 to 1997. Over and above his work experience, he boasts over 70 publications and holds 15 patents.

Founded in 1998, Seattle Genetics is a renowned cancer research and drug company with a diverse portfolio of clinical and preclinical products targeting a variety of cancer and autoimmune indications. Under Siegall’s leadership, Seattle genetics has raised over $1.2 billion in capital through public and private financing, including the company’s 2001 initial public offering. Moreover, the company has entered into multiple strategic collaborations with the most notable one being the exclusive worldwide collaboration agreement with Genentech for SGN-40 with a value of more than $860 million. Siegall has steered the company into being the industry and market leader in development and commercialization of antibody-drug conjugates (ADCs) with ADCETRIS as its first FDA approved and commercialized ADC product.

Siegall has been a recipient of praises from the world and awards of excellence throughout his career. In his blog, Public Access on engadget, Jesse Boskoff refers to Clay Siegall as a person with a deep passion and a true commitment to improve the lives of cancer patients. This desire to alleviate such patients’ suffering has enabled Siegall to facilitate his company in undertaking advanced research on cancer and cancer drugs using the most innovative technology. Among the numerous awards that crown Siegall’s professional achievements are the 2013 University of Maryland Alumnus of the Year for Computer, Math and Natural Sciences and the 2012 Pacific Northwest Ernst & Young Entrepreneur of the Year. Even with such a remarkable track record, Siegall shows no signs of slowing down in his efforts to fight cancer. In fact, he plans on rolling out 12 new cancer therapy drugs.